For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 41,134 | 42,090* | 38,347 | 32,275 |
| General and administrative | 6,874 | 8,428* | 7,220 | 9,070 |
| Total operating expenses | 48,008 | 50,518 | 45,567 | 41,345 |
| Loss from operations | -48,008 | -50,518* | -45,567 | -41,345 |
| Interest income and other, net | 2,618 | 4,219* | 3,714 | 4,391 |
| Loss before income taxes | -45,390 | -46,300* | -41,853 | -36,954 |
| Income tax expense | 50 | -6,766* | 196 | 207 |
| Net loss | -45,440 | -39,534* | -42,049 | -37,161 |
| Unrealized loss on available-for-sale investments | -271 | -239* | 201 | -81 |
| Comprehensive loss | -45,711 | -39,773 | -41,848 | -37,242 |
| Basic EPS | -0.57 | -0.487 | -0.53 | -0.44 |
| Diluted EPS | -0.57 | -0.487 | -0.53 | -0.44 |
| Basic Average Shares | 79,198,204 | 81,686,567 | 79,052,154 | 83,747,335 |
| Diluted Average Shares | 79,198,204 | 81,686,567 | 79,052,154 | 83,747,335 |
Atea Pharmaceuticals, Inc. (AVIR)
Atea Pharmaceuticals, Inc. (AVIR)